Relapsing-remitting MS (RRMS): RRMS is characterized by unpredictable but clearly defined relapses (also known as attacks, exacerbations or flare-ups) during which new symptoms appear or existing ones ...

Columnist Ben Hofmeister, while searching for motivation in a life with multiple sclerosis, feels he just needs to get around to it.

The onset of multiple sclerosis (MS) in older individuals correlates with a higher risk of developing primary progressive MS, faster progression to secondary progressive MS, and increased disability ...

Multiple sclerosis (MS ... most people have relapsing-remitting MS. Other types include primary progressive MS, secondary progressive MS, and clinically isolated MS. Contact your doctor if ...

Susie Wyss used to inject herself daily with a medication for multiple sclerosis. “The injection hurt. It caused welts, bruises, and sometimes permanent lipoatrophy,” Wyss told more than 800 people ...

Susie Wyss used to inject herself daily with a medication for multiple sclerosis. “The injection hurt. It caused welts, bruises, and sometimes permanent lipoatrophy,” Wyss told more than 800 people ...

According to the MS Society, certain medications like ocrelizumab (Ocrevus) can slow the progression of the disease in primary progressive multiple sclerosis, and syponimod (Mayzent) can help with ...

Nov. 18, 2024 — Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in ...

Its pipeline products include PIPE-791, an LPA1 receptor antagonist for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PMS); PIPE-307, a selective inhibitor of the M1 receptor ...

During his departure announcement in 2024, Neil thanked his bosses for their patience when he took off “a day or two here and there battling everything from multiple sclerosis and COVID to ...

Disappointingly, evobrutinib did not outperform teriflunomide on the primary outcome ... be less effective in relapsing than in progressive disease. Trials including participants with progressive ...